Novozymes delivers resilient full-year results despite the COVID-19 pandemic and is confident about getting back to growth in 2021


Novozymes delivered flat organic sales growth in the 2020 financial year and an EBIT margin of 26.1%. In 2021 the company expects 2-6% organic growth supported by innovation, stronger commercial presence, and gradual industry recovery. EBIT margin is expected at a solid 25-26%.

Excerpt from:
Novozymes delivers resilient full-year results despite the COVID-19 pandemic and is confident about getting back to growth in 2021

Related Posts